Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumor Malignancies 1

Interventions

fludarabine 5Cyclophosphamide 5Surgical Procedures, Operative 2Standard of Care 2Immune Checkpoint Inhibitors 2Bevacizumab 2venetoclax 1tucatinib 1trifluridine tipiracil drug combination 1tremelimumab 1trastuzumab deruxtecan 1tislelizumab 1tipiracil 1spartalizumab 1sotorasib 1semaglutide 1selpercatinib 1posaconazole 1pembrolizumab 1peginterferon alfa-2b 1osimertinib 1montelukast 1malic acid 1icotinib 1gallium maltolate 1encorafenib 1eliglustat 1durvalumab 1daratumumab 1cannabigerol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Not yet recruiting × malic acid × Clear all
NCT07325123 2026-01-08

Malic Acid Supplementation Combined With Immunotherapy in Patients With Solid Tumors

The First Affiliated Hospital of Xinxiang Medical College

Phase EARLY_PHASE1 Not yet recruiting
30 enrolled
Other solid neoplasm

Solid Tumor Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡